Source comparison
MK-677 Studied Muscle Tear: Research vs Supplement Comparison
Dosing Protocol 25mg once daily, evening administration, 4–8 week cycles aligned with injury timeline Variable (10–30mg), no timing guidance, often marketed for continuous use Research dosing is precise and phase-specific. Supplement guidance is generic Purity
This comparison does not assign a generated winner or score.
- Dosing Protocol
- 25mg once daily, evening administration, 4–8 week cycles aligned with injury timeline
- Variable (10–30mg), no timing guidance, often marketed for continuous use
- Research dosing is precise and phase-specific. Supplement guidance is generic
- Purity Verification
- Pharmaceutical-grade synthesis with HPLC verification, batch-tested for identity and potency
- Third-party testing varies, no standardized verification, contamination risk with under-regulated sources
- Real Peptides provides HPLC-verified MK-677 with batch-specific purity documentation. Recreational sources often lack traceability
- Primary Outcome Measured
- Lean body mass, collagen synthesis markers (procollagen type III), tensile strength of repaired tissue
- Weight gain, 'muscle fullness', subjective recovery perception
- Clinical outcomes are quantifiable biomarkers. Supplement claims rely on self-reported perception
- Injury Phase Target
- Mid-proliferative through remodeling (days 4–42 post-injury), not acute inflammation
- No phase-specific guidance, often implied for immediate post-injury use
- Mistimed use during acute inflammation wastes the compound's mechanism. Clinical protocols avoid this
- IGF-1 Elevation Pattern
- Sustained increase of 60–90% above baseline, maintained throughout dosing period
- Claimed but rarely verified with bloodwork
- Elevation without timing context is meaningless. The 18–24 hour availability window is what supports repair